Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Rummel, Mathias; Al-Batran, S.; Kim, Soo-Z.; Welslau, Manfred; Hecker, Ralf; Kofahl-Krause, Dorothea; Josten, Klaus-M.; Dürk, Heinz; Rost, Andreas; Neise, Michael; Grünhagen, Ulrich von; Chow, Kai Uwe; Hansmann, M. L.; Hoelzer, Dieter; Mitrou, Paris S.

doi:10.1200/jco.2005.08.100

Cited by 404 publications

(273 citation statements)

References 16 publications

(1 reference statement)

Supporting

Mentioning

258

Contrasting

Unclassified

Order By: Relevance

“…Additionally, recent data have suggested that bendamustine, either alone or in combination with rituximab, may be effective in patients with relapsed disease. 68 The consensus panel from the Fourth International Workshop on Waldenström's Macroglobulinemia also noted that autologous or allogeneic stem cell transplant should be considered in patients with high-risk disease. 11 High-dose therapy followed by autologous stem cell transplant has been performed in a growing number of patients with Waldenström macroglobulinemia.…”

Section: Treatment Of Relapsed Patientsmentioning

confidence: 99%

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

Ansell

Kyle

Reeder

et al. 2010

Mayo Clinic Proceedings

148

147

View full text Add to dashboard Cite

Section: Treatment Of Relapsed Patientsmentioning

confidence: 99%

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

Ansell

Kyle

Reeder

et al. 2010

Mayo Clinic Proceedings

148

147

View full text Add to dashboard Cite

“…More promising data on the contrary have been recently achieved from the new combination of some 'old drugs' with rituximab, based on the results of the bendamustin-rituximab regimen (75% overall response rate, ORR -and 50% complete responses, CR -in relapsing disease) [16]. The impressive activity of bendamustin-rituximab has been also shown in first-line treatment [17], as well as the superior data of cytarabine in first-line young patients [6][7][8].…”

Section: Chemotherapy-based Approachesmentioning

confidence: 99%

The current therapeutic scenario for relapsed mantle cell lymphoma

Ferrero

Dreyling

2013

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewPatients with relapsing mantle cell lymphoma (MCL) still represent a demanding challenge for the hematooncologist. The dismal prognosis and the absence of generally accepted therapeutic standards hamper the clinical management of such cases. Moreover, the availability of many targeted approaches, in a field so far missing efficient salvage regimens, challenges current therapeutic algorithms in these patients. Recent findingsMolecular targeted drugs provide unprecedented response rates in relapsed and even chemorefractory MCL. Many phase II studies demonstrated impressive antilymphoma activity of compounds such as bortezomib, lenalidomide and temsirolimus, whereas ongoing phase III trials currently assess the 'real world' benefit and the impact on survival, both alone and in combination with chemotherapy or monoclonal antibodies. Recently, the Bruton's tyrosine kinase inhibitor ibrutinib, targeting the B-cell receptor cascade, showed impressive response rates and will be soon available in phase III trials. SummaryIn the present review we focus on the major therapeutic discoveries of the last few years to offer a practical algorithm to select the appropriate treatment in patients with relapsed MCL.

show abstract

“…Thalidomide and lenalidomide have shown modest activity in relapsed disease, suggesting possible enhanced activity in the frontline setting. [30][31][32] Rummel et al 33 reported on the activity of bendamustine combined with rituximab in relapsed lowgrade lymphoma and MCL. Only 16 patients enrolled on that study had MCL histology, but the overall response rate of 75% (CR 50%) in this subset supported studying this agent in randomized trials.…”

Section: New Chemotherapy Agentsmentioning

confidence: 99%

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Nabhan

Ragam

Bitran

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

The role of hematopoietic SCT (HSCT) in mantle cell lymphoma (MCL) remains controversial. Most studies that support the utility of this approach were small phase II single-institution studies with highly selected patient populations. Furthermore, recent evidence suggesting initial observation as opposed to immediate therapy in MCL, coupled with the availability of newer therapeutic agents, complicates the role of HSCT and argues for conducting large phase III studies. In this review, we discuss the limitation of current evidence and the lack of large definitive studies. We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making.

show abstract

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Abstract: These results demonstrate that the BR combination is a highly active regimen in the treatment of low-grade lymphomas and mantle cell lymphomas.

Cited by 404 publications

References 16 publications

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

The current therapeutic scenario for relapsed mantle cell lymphoma

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Contact Info

Product

Resources

About